Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $178 from $177 and keeps an Outperform rating on the shares following the ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Quest Diagnostics (DGX) to $180 from $165 and keeps a Neutral rating ...

Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancer screening is highly accurate.

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...